Belinda Presley
Family · Bartlett, TNNPI 1639114671
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,760 of the $33,446 with a category attached, or 71.0%. 31 manufacturers reported payments, led by Dexcom, Inc. at 58.4% of the total. Reporting peaked in 2021 at $24,098 and has fallen 90.2% since, to $2,355 in 2025. Among family clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 484 payments — averaging $69.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$20K
- AstraZeneca$6K
- Boehringer Ingelheim$1K
- Lilly USA, LLC$1K
- Novo Nordisk$989
- Corcept Therapeutics$850
- plus $3K from 25 others
What the payments were for
- Speaking & faculty fees$23,76071%
- Travel & lodging$7722%
- Food & beverage$8,91327%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 66 | $19,524 |
| AstraZeneca | 25 | $6,495 |
| Boehringer Ingelheim | 62 | $1,289 |
| Lilly USA, LLC | 61 | $1,043 |
| Novo Nordisk | 66 | $989 |
| Corcept Therapeutics | 38 | $850 |
| Insulet Corporation | 21 | $377 |
| Xeris Pharmaceuticals, Inc. | 22 | $369 |
| Mannkind Corporation | 22 | $332 |
| BETA Bionics, Inc. | 5 | $254 |
| Amarin Pharma, Inc. | 14 | $229 |
| Amgen | 6 | $161 |
| AbbVie | 12 | $161 |
| Bayer | 9 | $151 |
| RGH Enterprises LLC | 3 | $139 |
| Ascensia Diabetes Care US Inc. | 7 | $134 |
| Sanofi-aventis U.S. LLC | 8 | $122 |
| Teva Pharmaceuticals USA, Inc. | 1 | $121 |
| Esperion Therapeutics, Inc. | 1 | $99 |
| Merck | 7 | $96 |
| Tandem Diabetes Care, Inc. | 5 | $88 |
| Medtronic | 5 | $78 |
| Abbott | 3 | $74 |
| Sequel Med Tech, LLC | 3 | $73 |
| Azurity Pharmaceuticals, Inc. | 3 | $46 |
| Amneal Pharmaceuticals LLC | 2 | $37 |
| IBSA Pharma Inc. | 2 | $34 |
| Endo Pharmaceuticals Inc. | 2 | $26 |
| Acella Pharmaceuticals, LLC | 1 | $20 |
| Antares Pharma, Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$18,609
- FARXIGA$6,127
- iLet Bionic Pancreas$444
- AJOVY$121
- Korlym$121
- JARDIANCE$111
How this compares
$33,446 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 280 | $329,082 |
| MounjaroTirzepatide | 218 | $255,942 |
| JardianceEmpagliflozin | 301 | $255,758 |
| Tresiba Flextouch U-200Insulin Degludec | 76 | $82,498 |
| Tresiba Flextouch U-100Insulin Degludec | 124 | $81,946 |
| SynjardyEmpagliflozin/Metformin Hcl | 92 | $65,136 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 59 | $64,272 |
| FarxigaDapagliflozin Propanediol | 54 | $44,838 |
| TrulicityDulaglutide | 26 | $42,256 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 37 | $28,371 |
| RybelsusSemaglutide | 19 | $28,174 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 153 | $27,429 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 25 | $23,703 |
| FiaspInsulin Aspart (Niacinamide) | 12 | $17,117 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $12,571 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $989 | $386,500348 claims |
| Boehringer IngelheimJardiance, Synjardy, Synjardy Xr | $1,289 | $344,597418 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $1,043 | $305,646287 claims |
| AstraZenecaFarxiga | $6,495 | $44,83854 claims |
| Sanofi-aventis U.S. LLCLantus | $122 | $5,62623 claims |
| AbbVieSynthroid | $161 | $3,25439 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $37 | $2,989381 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.
Other family in Bartlett
- Stacy ScrewsBartlett$58K
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.